Clinical Trials Logo

Filter by:
NCT ID: NCT03260894 Active, not recruiting - Clinical trials for Renal Cell Carcinoma (RCC)

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Start date: December 7, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not received prior systemic therapy for their mRCC.

NCT ID: NCT03252353 Active, not recruiting - Acromegaly Clinical Trials

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

OPTIMAL
Start date: September 1, 2017
Phase: Phase 3
Study type: Interventional

Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated maintenance of biochemical response up to 13 months in the majority of patients with acromegaly previously managed with somatostatin analog injections (reference below).

NCT ID: NCT03228485 Active, not recruiting - Clinical trials for Lower Urinary Tract Symptoms

Benign Prostatic Hyperplasia (BPH) Mobile Application Pilot Study

Start date: April 4, 2019
Phase:
Study type: Observational

This study assesses the feasibility, and acceptability of a (mobile) application for men presenting at their physician's office with LUTS/BPH; starting with medical therapy and naïve for treatment. Patients will be enrolled in the study by their physician (GP or urologist). The patients will receive a daily medication reminder including frequent feedback on medication adherence. Furthermore, standard questionnaires will be filled out via the application. The hypothesis of this pilot study is that application is feasible and accepted in this group of patients.

NCT ID: NCT03227042 Active, not recruiting - Clinical trials for Mucopolysaccharidosis Type IIIB

A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)

Start date: November 16, 2017
Phase:
Study type: Observational

This is a natural history study for children up to 18 years of age who have been diagnosed with Mucopolysaccharidosis Type IIIB (MPS IIIB, also known as Sanfilippo Syndrome Type B). Mucopolysaccharidosis type IIIB is a severe neurodegenerative disorder. The information gathered from this trial may help inform the design and interpretation of subsequent interventional studies. No clinical intervention or study drug is provided by Allievex in this study.

NCT ID: NCT03215030 Active, not recruiting - Multiple Myeloma Clinical Trials

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

iinnovate-1
Start date: October 4, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The main aims of this 3-part study are as follows: Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occur. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Part 2: To assess clinical activity of one or more dosing schedules of modakafusp alfa alone in participants with relapsed/refractory multiple myeloma. Dexamethasone standard dose will be administered with one or more selected dose of modakafusp alfa in selected group of participants. Part 3: To find the optimal dose with the more favorable risk-benefit profile of modakafusp alfa. Participants will receive modakafusp alfa at one of two doses which will be given through a vein.

NCT ID: NCT03201965 Active, not recruiting - Amyloidosis Clinical Trials

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Start date: October 5, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.

NCT ID: NCT03194646 Active, not recruiting - Uterine Fibroids Clinical Trials

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

ASTEROID 6
Start date: June 30, 2017
Phase: Phase 3
Study type: Interventional

The study was performed to assess the efficacy and safety of Vilaprisan in subjects with uterine fibroids compared to standard of care

NCT ID: NCT03182374 Active, not recruiting - Clinical trials for Osteoarthritis, Knee

nSTRIDE APS Versus Hyaluronic Acid for Knee Osteoarthritis

Start date: July 14, 2017
Phase: N/A
Study type: Interventional

This is a two-phase multicenter, double-blind, randomized, prospective evaluation of intra-articular injection(s) comparing APS to intra-articular HA injection(s). The maximum study duration for each subject will be 62 months; 60 months from treatment to last follow-up, and two additional months if the maximum visit window is realized. A total of 246 patients will be enrolled. These patients will meet specific inclusion and exclusion criteria, but can be generally characterized as patients with painful unilateral knee OA who have been unable to achieve satisfactory pain relief with previous conservative OA treatment.

NCT ID: NCT03180736 Active, not recruiting - Multiple Myeloma Clinical Trials

Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone

EMN14
Start date: June 12, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effects of the addition of daratumumab to pomalidomide and dexamethasone in terms of progression-free survival in subjects with relapsed or refractory Multiple Myeloma.

NCT ID: NCT03173521 Active, not recruiting - Clinical trials for Mucopolysaccharidosis Type VI

Gene Therapy in Patients With Mucopolysaccharidosis Disease

Start date: July 17, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This study investigated the safety and efficacy of gene therapy approaches for Mucopolysaccharidosis type VI disease caused by the deficiency of arylsulfatase B (ARSB) enzyme. The aim of the study is to evaluate the safety and efficacy of the treatment.